{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:24:26Z","timestamp":1790504666249,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000150","name":"Canadian Breast Cancer Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nucmedbio.2019.10.001","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T11:45:13Z","timestamp":1571744713000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR"],"prefix":"10.1016","volume":"80-81","author":[{"given":"Conrad","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Fonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0005","first-page":"148","article-title":"Management of metastatic HER2-positive breast cancer: where are we and where do we go from here?","volume":"30","author":"Santa-Maria","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"NEnglJ Med"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0015","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-009-0592-x","article-title":"EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance","volume":"122","author":"Dua","year":"2010","journal-title":"Breast Cancer ResTreat"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0035","first-page":"1003","article-title":"T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways","volume":"10","author":"Endo","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2012.85","article-title":"Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas","volume":"106","author":"Gallardo","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0045","first-page":"79","article-title":"Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas","volume":"7","author":"Changavi","year":"2015","journal-title":"J Lab Phys"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","article-title":"Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development","volume":"53","author":"Costa","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2967\/jnumed.108.051771","article-title":"Trastuzumab-resistant breast cancer cells remain sensitive to the Auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate","volume":"49","author":"Costantini","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy - a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2307\/3578051","article-title":"The question of relative biological effectiveness and quality factor for auger emitters incorporated into proliferating mammalian cells","volume":"128","author":"Howell","year":"1991","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0075","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2967\/jnumed.109.072389","article-title":"Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts","volume":"51","author":"Costantini","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1667\/RR1359.1","article-title":"Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons","volume":"170","author":"Pouget","year":"2008","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0085","first-page":"3","article-title":"Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications","volume":"23","author":"Costantini","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-012-2137-y","article-title":"111In-Bn-DTPA-nimotuzumab with\/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer","volume":"135","author":"Fasih","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"10.1016\/j.nucmedbio.2019.10.001_bb0105","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1074\/jbc.M610014200","article-title":"Characterization of a novel tripartite nuclear localization sequence in the EGFR family","author":"Hsu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0110","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0115","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-05-1109","article-title":"Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts","volume":"12","author":"DuManoir","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0120","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients","volume":"22","author":"Crombet","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0125","series-title":"Drugs directorate guidelines for toxicologic evaluation","author":"Anonymous","year":"1995"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4161\/mabs.28915","article-title":"Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor","volume":"6","author":"Tundidor","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0135","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V85.9.2385.bloodjournal8592385","article-title":"Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin","volume":"85","author":"Waltz","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0140","first-page":"181","article-title":"Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of 111In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer","volume":"4","author":"Vallis","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0145","first-page":"903","article-title":"A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer","volume":"41","author":"Reilly","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2017.06.001","article-title":"Synergistic anti-tumor activity of nimotuzumab in combination with trastuzumab in HER2-positive breast cancer","volume":"489","author":"Yang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0155","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s10637-010-9444-0","article-title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","volume":"29","author":"You","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/09553000902748757","article-title":"Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to 111In-DTPA-hEGF or gamma-rays using image-J software","volume":"85","author":"Cai","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-019-0633-6","article-title":"Antibody-drug conjugates in breast cancer: a comprehensive review","volume":"20","author":"Ponde","year":"2019","journal-title":"Curr Treat Options Oncol 20"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0170","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.18632\/oncotarget.26613","article-title":"Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft","volume":"10","author":"Hartimath","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2019.10.001_bb0180","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.118.220095","article-title":"Preclinical evaluation of 111In-labeled PEGylated maytansine nimotuzumab drug conjugates in EGFR-positive cancer models","author":"Hartimath","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119301131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119301131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:50Z","timestamp":1760848130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805119301131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"alternative-id":["S0969805119301131"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.10.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}